We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
14
Research Clients
101
Reports published
10k+
Readers in database
Read our @HChiMed Update note covering #Elunate commercial progress to date, highlighting upcoming #savolitinib #NSCLC data at #aacr2019 , & our updated estimates post-FY18 $HCM $HCM.L https://t.co/WrQb4WeQhK
Read our note on @NexstimOyj as it looks to securing the commercial future of NBT in depression at https://t.co/qQmPY3Dxtz
We highlight that @HChiMed has global development #collaborations for PD-1 combos with Innovent (Tyvyt) for #fruquintinib and Junshi (Tuoyi) for #surufatinib $HCM
.@HChiMed's wholly owned #VEGFR inhibitor #surufatinib features in the latest @TheLancetOncol
Interim Phase III data from the #China SANET-p and SANET-ep trials in NET (#neuroendcrine tumours) are expected later in 2019 $HCM
The timeline for the next China #NDRL update are clearer, with potential for inclusion of @LillyPad and @HChiMed's cancer drug #Elunate (#fruquintinib) this year $HCM
US portfolio expansion underway as @BONESUPPORT_AB launches the #BONIFY 100% DBM bone graft range at #AAOS2019.
#BONIFY's #osteoinductive properties complement the #osteoconductive #CERAMENT platform. Both products will be sold via $BONEX's direct US distributor network.
Please sign up here to be added to our distribution database
